ADD-196022 is an orally active antiepileptic and anticonvulsant agent. ADD-196022 shows ED50 values of 26.2 mg/kg and 5.79 mg/kg for intraperitoneal injection in mice and orally administration in rats. ADD-196022 can be used for the research of neurological disease.

ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan. Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody.

Adavosertib (AZD1775; MK-1775) acid (Compound 9) is a derivative of AZD1775 and can be used for the synthesis of PROTAC.

Ac-N-m-(CF3)2-Ph-C-Py (Compound F31) is an electrophilic fragment. Ac-N-m-(CF₃)₂-(phenyl)-C-(pyridyl) can be used in proteomics research.

Aclatonium napadisylate is a cholinergic agonist. Aclatonium napadisylate can increase amylase release and Ca2+ efflux. Aclatonium napadisylate can stimulate pancreatic exocrine secretion and increase motility and peristalsis of the gastrointestinal tract. Aclatonium napadisylate can be used for the research of gastrointestinal disorders.

ACI-19278 is a TDP-43 PET tracer with an average Kd of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [18F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions.

ACHM-025 is a prodrug, which is selectively activated by AKR1C3 to a nitrogen mustard DNA alkylating agent. ACHM-025 can be used for the research of cancer, such as leukemia.

AChE-IN-98 (Compound 26) is an AChE inhitibor, with an IC50 value of 7.3 μM for ee AChE. AChE-IN-98 is also a Coumarin derivative. AChE-IN-98 can be used in the research of Alzheimer's disease.

AChE-IN-105 (Compound C5) is a potent, mixed AChE inhibitor with an IC50 of 5.02 μM. AChE-IN-105 scavenges ROS, decreases Hydrogen peroxide-induced Caspase-3 activation, reduces activity of the Nrf2-ARE pathway. AChE-IN-105 prevents memory impairments in the Scopolamine-induced cognitive dysfunction zebrafish model. AChE-IN-105 has potent antioxidant activity. AChE-IN-105 can be used in the research of Alzheimer's disease.

AChE-IN-103 (Compound 10) is an inhibitor of ACh. AChE-IN-103 exhibits log IC50 values of 1.477 and 2.2 for models based on alignments I and II. AChE-IN-103 can be studied in research on Alzheimer’s disease.

AChE/MAO-B-IN-9 (Compound E12) is an orally active, selective, reversible, non-competitive AChE and MAO-B inhibitor, with an IC50 of 0.156 μM against electric eel AChE. AChE/MAO-B-IN-9 inhibits Aβ40/42 fibril formation, promotes Aβ fibril depolymerization, and inhibits Tau protein fibril formation. AChE/MAO-B-IN-9 exerts antioxidant and neuroprotective effects, and improves scopolamine-induced memory impairment in mice. AChE/MAO-B-IN-9 can be used for the research of Alzheimer's disease.

Acalabrutinib (Calquence) maleate is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib maleate demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib maleate can be used for CLL research. Acalabrutinib maleate is a click chemistry reagent, which contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

ABH is an arginase 1 (ARG1) inhibitor, with an IC50 of 311 nM against hARG1.

ABCA1 inducer 3 (Compound 85) is an orally active ABCA1 inducer and lipid-modulating agent. ABCA1 inducer 3 increases ABCA1 expression. ABCA1 inducer 3 upregulates hepatic Abcg5 and Abcg8 mRNA expression. ABCA1 inducer 3 promotes cholesterol efflux. ABCA1 inducer 3 improves hyperlipidemia.

ABC transporter modulator-5 (I-677-Isomer 2 (R configuration)) is a ABC modulator. ABC transporter modulator-5 is used in studies of ABC dysfunction.

ABCC6 modulator-3 (Compound I-71) is a ABCC6 activator with an EC50 < 1 μM. ABCC6 modulator-3 upregulates the expression of wild-type ABCC6. ABCC6 modulator-3 is used in research on diseases associated with ABC transporter dysfunction.

ABC transporter modulator-2 (Compound I-200) is a ABC transporter expression modulator. ABC transporter modulator-2 upregulates the expression of wild-type ABCC6 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCB4 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCD2 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of the ABCA4P1380L mutant with an EC50 of <1 μM. ABC transporter modulator-2 can be used in the research of diseases associated with ABC transporter dysfunction.

ABC transporter modulator-1 (Compound I-5) is an ABC transporter expression enhancer. ABCC6 modulator-1 upregulates the expression of wild-type ABCC6, wild-type ABCB4, and ABCA4P1380L mutant, with an EC50 of <1 μM for all.

AB-22, a vinyl sulfate compound, is an orally active antifungal agent. AB-22 inhibits hyphal growth and biofilm initiation by inhibiting the gene expression of ALS3, HWP1, and ECE1 in Candida albicans SC5314 cells. AB-22 can be used for the research of infrction, such as systemic candidiasis.

AAK1-IN-12 (Compound 4) is a selective, orally active AAK1 inhibitor that can cross the blood-brain barrier. AAK1-IN-12 is applicable to the research of schizophrenia, Parkinson's disease, neuropathic pain and Alzheimer's disease.

A-837093 sodium is a potent and orally active inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase. A-837093 sodium shows potencies against polymerases derived from both HCV genotypes 1a (IC50 = 1.25 nM) and 1b (IC50 = 0.33 nM). A-837093 sodium exhibits antiviral efficacy in HCV-infected chimpanzees. A-837093 sodium can be used for HCV infection research.

A-348441 is a liver selective glucocorticoid receptor antagonist. A-348441 can reduce the glucose level in the liver. A-348441 can be used for the research of metabolic disease, such as type 2 diabetes.

A 131701 is a selective α1a- (Ki: 0.22 nM for human α1a) and α1d-adrenoceptor antagonist. A 131701 antagonizes epinephrine-induced increases in intraurethral pressure (IUP). A 131701 causes transient decreases in mean arterial blood pressure (MABP) and transient tachycardia. A 131701 can be used in the research of spontaneous hypertension.

9-Thiastearic acid is a fatty acid.

9-Deoxyforskolin (compound 2) is a labdane-type diterpenoid, and also a forskolin derivative identified in hairy root cultures of Coleus forskohlii.

9,10-Epoxy13-hydroxy-11-octadecenoic acid is a fatty acid.

9(Z),12(E)-Octadecadienoic acid is an unsaturated fatty acid.

9(E)-Monohexadecenoin is an acylglycerol.

8-Oxo-Δ9-THC is an oxygenated tetrahydrocannabinol that can be found in Cannabis sativa L. variety CHPF-01.

8-Bromooctan-1-ol (8-Bromo-1-octanol) is a PROTAC linker that can be used in the synthesis of PROTACs.